Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Mesopic Microperimetry: Performance of the New MAIA Device in Healthy Controls
Author Affiliations & Notes
  • CHIARA RUI
    Centervue SpA, Italy
  • Silvia Gazzina
    Centervue SpA, Italy
  • Petra Rossouw
    Universitatsspital Basel, Augenklinik, Switzerland
    Institute of Molecular and Clinical Ophthalmology Basel, Switzerland
  • Georg Ansari
    Universitatsspital Basel, Augenklinik, Switzerland
    Institute of Molecular and Clinical Ophthalmology Basel, Switzerland
  • Kristina Pfau
    Universitatsspital Basel, Augenklinik, Switzerland
    Institute of Molecular and Clinical Ophthalmology Basel, Switzerland
  • Maximilian Pfau
    Universitatsspital Basel, Augenklinik, Switzerland
    Institute of Molecular and Clinical Ophthalmology Basel, Switzerland
  • Footnotes
    Commercial Relationships   CHIARA RUI Centervue SpA, Code E (Employment); Silvia Gazzina Centervue SpA, Code E (Employment); Petra Rossouw None; Georg Ansari None; Kristina Pfau Daiichi Sankyo, Code C (Consultant/Contractor); Maximilian Pfau Daiichi Sankyo, Code C (Consultant/Contractor), Centervue SpA, Code F (Financial Support), Apellis, Code F (Financial Support), Belite Bio, Code F (Financial Support)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 5389. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      CHIARA RUI, Silvia Gazzina, Petra Rossouw, Georg Ansari, Kristina Pfau, Maximilian Pfau; Mesopic Microperimetry: Performance of the New MAIA Device in Healthy Controls. Invest. Ophthalmol. Vis. Sci. 2024;65(7):5389.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the agreement and repeatability of the new MAIA (MAIA3) microperimeter compared with MAIA 2013 EDITION (MAIA2) on healthy subjects

Methods : Thirty healthy subjects (mean Sensitivity Range [25.50, 29.18] dB for MAIA3, [25.37, 29.38] dB for MAIA2) underwent a total of four microperimetric (MP) exams on one randomly selected eye. MP exams were performed in two sessions within one week (one exam per device in each session). MP tests were collected using a 4-2 strategy and a 10-2 grid (68 locations) plus the fovea. MP exams with Fixation Losses >30% and average pupil size during tests >2.8 mm (based on MAIA3) were considered unreliable and excluded. A total of 120 MP exams were analyzed. The agreement between the two devices and the intra-device test-retest (TRT) repeatability was evaluated both globally with Mean Sensitivity (MS) and pointwise (PWS) with Bland-Altman technique (95% Confidence Interval (CI) for Mean Difference (MD), Limits of Agreement (LoA), Limits of Repeatability (LoR)). The exam durations for both devices (average difference and distribution) were investigated, as shown in Figure2

Results : Regarding the agreement, the MD between MAIA3 and MAIA2 was -0.36 dB. Thus, on average, MAIA3 slightly underestimated MAIA2 by a non-clinically significant amount (< 1 dB). MAIA3 95%CI LoA (MS [-2.27, +1.55] dB, PWS [-4.59, +3.87] dB) were respectively narrower than MAIA2 LoR (MS [-2.04, +1.93] dB, PWS [-4.00, +3.89] dB) by -0.16 dB for MS and wider by +0.57 dB for PWS.
Intra-device MD was close to 0dB (-0.04dB MAIA3, -0.05dB MAIA2). MAIA3 95%CI LoR (MS [-1.56, +1.48] dB, PWS [-3.84, +3.76] dB) were narrower than MAIA2 LoR (MS [-2.04, +1.93] dB, PWS [-4.00, +3.89] dB) by -0.94dB for MS and by -0.30 dB for PWS, as reported in Figure1.
The average difference in exam duration between MAIA2 and MAIA3 (494.08 and 472.97 seconds) was 21.11 seconds.

Conclusions : MAIA3 agreed well with MAIA2 exams globally and at the point-wise level with a minimal bias (<0.5 dB). MAIA3 achieved better TRT repeatability than MAIA2, narrowing the LoR by almost 1 dB. The average exam duration was reduced by more than 20 seconds for MAIA3. These data on healthy subjects suggest that MAIA3 and MAIA2 can be used interchangeably. The external validation study in patients is ongoing (NCT06071546)

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

Figure1. Bland-Altman of MAIA3 and MAIA2 for Agreement and Repeatability, MS and PWS

Figure1. Bland-Altman of MAIA3 and MAIA2 for Agreement and Repeatability, MS and PWS

 

Figure2. Exam duration distribution for MAIA3 and MAIA2

Figure2. Exam duration distribution for MAIA3 and MAIA2

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×